- Home
- About
- Team
- Today's Market
- Premium
- Research it
- Outlook
- Portfolio
- Mobile
- Trust Equitymaster
- Help
- Free Reports
MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Stock Quote
- Sector Info (pharmaceuticals)
- Indian Pharma
Indian Pharma Stocks 
Here are the latest stock price details of India's top Indian Pharma stocks. For more detailed updates, read our Indian Pharma sector report and check the latest Indian Pharma sector results.
| SCRIP | BSE PRICE (Rs) | NSE PRICE (Rs) | CHART | GET MORE INFO |
|---|---|---|---|---|
| AARTI DRUGS | 551.70 1.03% | 549.25 0.66% | More Info
|
|
| AJANTA PHARMA | 1,196.80 0.71% | 1,195.90 0.65% | More Info
|
|
| ALEMBIC PHARMA | 589.10 -1.18% | 590.45 -0.91% | More Info
|
|
| BIOCON LTD | 592.10 -0.80% | 591.30 -1.06% | More Info
|
|
| CADILA HEALTHCARE | 356.80 4.99% | 357.25 5.01% | More Info
|
|
| CIPLA | 648.15 0.12% | 646.90 -0.22% | More Info
|
|
| DIVIS LABORATORIES | 1,173.00 0.85% | 1,174.75 0.89% | More Info
|
|
| GLENMARK PHARMA | 600.15 2.91% | 600.15 2.90% | More Info
|
|
| INDOCO REMEDIES | 198.45 1.07% | 198.90 0.30% | More Info
|
|
| IPCA LABS | 731.40 -0.18% | 733.25 -0.14% | More Info
|
|
| J.B.CHEMICALS | 307.65 -1.00% | 308.15 -0.64% | More Info
|
|
| LUPIN LTD | 879.35 3.53% | 881.25 3.71% | More Info
|
|
| NATCO PHARMA | 752.50 0.05% | 754.40 0.33% | More Info
|
|
| NIFTY 50 | Not Listed | 11,470.75 0.75% | More Info
|
|
| ORCHID PHARMA LTD | 7.41 -2.88% | 18.90 -2.83% | More Info
|
|
| PANACEA BIOTECH | 231.85 3.16% | 230.60 2.08% | More Info
|
|
| PIRAMAL ENTERPRISES | 2,706.35 -0.17% | 2,703.20 -0.30% | More Info
|
|
| S&P BSE SENSEX | 37,947.88 0.75% | Not Listed | More Info
|
|
| STRIDES SHASUN LTD | 449.35 4.09% | 449.10 4.01% | More Info
|
|
| SUN PHARMA | 623.30 0.60% | 623.50 0.61% | More Info
|
|
| TORRENT PHARMA | 1,766.70 3.98% | 1,765.90 3.87% | More Info
|
|
| WOCKHARDT LTD. | 624.60 1.01% | 625.35 1.11% | More Info
|
BSE prices: August 17, 2018 (Close) NSE prices: August 17, 2018 (Close)
Indian Pharma Stocks Update
The NIFTY PHARMA Index was at 9,693.9 (up 1.0%). The index is up 8.6% over the last 30 days. And over the last 1 year, it has gained 10.2%.
Within the Indian Pharma sector, the top gainers were CADILA HEALTHCARE (up 5.0%) and STRIDES SHASUN LTD (up 4.1%). On the other hand, ORCHID PHARMA LTD (down 2.9%) and ALEMBIC PHARMA (down 1.2%) were among the top losers.
Meanwhile, the benchmark NIFTY 50 was at 11,470.8 (up 0.8%).
|
| |
Today's Market
Sensex Ends 284 Points Up; FMCG & Metal Stocks Top Gainers(Closing)
Indian share markets settled higher today taking cues from their Asian peers. At the closing bell, BSE Sensex ended up by 284 points.
Related Views on News
TORRENT PHARMA at 52 Week High; BSE 500 Index Up 1.0% (Market Updates)
Aug 17, 2018 | Updated on Aug 17, 2018TORRENT PHARMA share price has hit a 52-week high. It is presently trading at Rs 1,770. BSE 500 Index is up by 1.0% at 15,508. Within the BSE 500, TORRENT PHARMA (up 4.2%) and EDELWEISS FINANCIAL (up 8.5%) are among the top gainers, while top losers are TECHNO ELECTRIC and ZENSAR TECHNOLOGIES.
DR. LAL PATHLABS LTD Surges by 7%; BSE HEALTHCARE Index Up 1.6% (Market Updates)
Aug 17, 2018 | Updated on Aug 17, 2018DR. LAL PATHLABS LTD share price has surged by 7% and its current market price is Rs 1,040. The BSE HEALTHCARE is up by 1.6%. The top gainers in the BSE HEALTHCARE Index are DR. LAL PATHLABS LTD (up 7.4%) and CADILA HEALTHCARE (up 5.4%). The top losers are THYROCARE TECHNOLOGIES and SANOFI INDIA (down 0.2%).
CADILA HEALTHCARE Surges by 5%; BSE HEALTHCARE Index Up 1.4% (Market Updates)
Aug 17, 2018 | Updated on Aug 17, 2018CADILA HEALTHCARE share price has surged by 5% and its current market price is Rs 358. The BSE HEALTHCARE is up by 1.4%. The top gainers in the BSE HEALTHCARE Index is CADILA HEALTHCARE (up 5.2%). The top losers are THYROCARE TECHNOLOGIES and PFIZER .
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)
Feb 9, 2018US business was hit by pricing pressure although there was growth sequentially led by new product launches.
More Views on NewsMost Popular
This is a Must-Have Stock for Your Portfolio(The 5 Minute Wrapup)
Aug 8, 2018Tanushree just released the permanent wealth blueprint report. This report includes three safe and steady stocks. I like one in particular. Here's why
Trading in These Times: 8% Gains in 3 Days!(Profit Hunter)
Aug 9, 2018Here are 2 stocks you can buy right now! And there are plenty more opportunities to come...
Banks are Raising FD Rates and That's Good News(Vivek Kaul's Diary)
Aug 7, 2018Lending to the retail segment remains strong, whereas lending to the service sector has picked up dramatically.
Why HDFC Equity Fund Disappointed Its Investors(Outside View)
Aug 9, 2018Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.
HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)
Aug 8, 2018PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.
More|
| |
S&P BSE HEALTHCARE
Aug 17, 2018 (Close)
S&P BSE HEALTHCARE 5-YR ANALYSIS
COMPARE COMPANY
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.